Key end points were ( 1 ) percentage of responders at 2 years ( ie , could consume 5 g of peanut powder or a 10-fold increase from baseline ) , ( 2 ) percentage reaching desensitization at 3 years , ( 3 ) percentage attaining sustained unresponsiveness after 3 years , ( 4 ) immunologic end points , and ( 5 ) assessment of safety parameters .